ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2012

Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease.

Andrew W Roberts et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.